Summary: Elevated LDL cholesterol is one of the main modifiable risk factors for the development of atherosclerotic cardiovascular disease. There is a simple linear relationship between LDL cholesterol levels and the risk of developing atherosclerotic cardiovascular disease. It has also been shown that the more pronounced the reduction in LDL cholesterol, the greater the reduction in cardiovascular risk. The drug of first choice in cholesterol-lowering therapy is statins. Long-acting and potent statins (atorvastatin, rosuvastatin) can reduce LDL-C levels by about 50%. However, this is not enough in many patients. Therefore, ezetimibe should be added to the treatment as a second step. This combination makes it possible to lower LDL-C by up to about 65%. Using the example of the combination of ezetimibe with atorvastatin in the form of a single pill combination, the article describes the possibility of using this combination in the treatment of hypercholesterolemia in patients at high cardiovascular risk.